In an annoucement today from Pfizer, the Government of Canada has entered into an agreement with the Pfizer and BioNTech to supply the partnership's BNT162 mRNA-based vaccine to combat COVID-19.
Pfizer is one of several companies who may potentially meet the Thanksgiving Vaccine moment. The company has announced potential availability of 100 million doses by October of this year. In the agreement, deliveries of the vaccine in Canada are estimated to take place over the course of 2021.
"This agreement is part of our commitment to address the pandemic by supporting global supply of our vaccine candidate. Our teams are working diligently to advance the lead product candidate through clinical development in order to seek regulatory review as early as October. At the same time, Pfizer andBioNTech continue to scale up manufacturing capacities to be able to produce up to 100m doses in 2020 and more than one billion doses in 2021. Since we initiated Project Lightspeed our aim has always been clear: Making a potential vaccine available to the public as quickly as possible – worldwide. This agreement is yet another step in that direction," said Sean Marett , Chief Business and Chief Commercial Officer at BioNTech.
In the partnership, BioNTech contributes a proprietary mRNA technology to Pfizer's full vaccine development. The companies are currently evaluating at least four vaccines as experimental candidates. While none are currently approved for use, two of the candidates, BNT162b1 and BNT162b2, earned a "Fast Track" approval from the FDA based on early results from Phase 1/2 studies in the U.S. and Germany in both humans and animals.
"As the development of effective COVID-19 vaccines continues around the world, we commend the work of Pfizer and BioNTech , which will provide Canadians access to a vaccine candidate for the virus. This agreement is another critical step in our government's efforts to keep Canadians safe and healthy as the pandemic continues to evolve," said The Honourable Anita Anand, Minister of Public Services and Procurement, Government of Canada.
Globally, the partnership expects to deliver up to 1.3 billion doses of their final vaccine by the end of next year, subject to regulatory approval. In addition to supplying their vaccine worldwide, the companies are in early talks with Gavi, the Vaccine Alliance in supplying their COVAX Facility. The COVAX facility aggregates a wide portfolio of COVID-19 vaccines from multiple manufacturers in partnership with the World Health Organization and the Coalition for Epidemic Preparedness Innovations.